

ASX Announcement

16 June 2026

Clarification of Key Terms – STC Distribution Agreement

ReNerve Limited (ASX, "ReNerve" or "the **Company**"), an Australian biotechnology company developing innovative products for peripheral nerve injury ("PNI") repair, refers to its ASX announcement dated 1 June 2026 titled "*Distribution agreement for broader Hong Kong market*" and provides the following additional information regarding its exclusive distribution agreement with Swedish Trading Company Limited ("STC").

Term and Renewal

The agreement has an initial term of three (3) years and may automatically renew for up to two (2) additional one-year periods (maximum five years), unless terminated with six (6) months' notice.

Exclusivity

STC has exclusive distribution rights in the territory for the term of the agreement, subject to customary conditions, including no material breach.

Performance Framework

Performance expectations are based on annual minimum purchase targets, with STC required to use commercially reasonable efforts to achieve those targets. The minimum purchase targets are currently being finalised between the parties and are expected to be agreed in the coming months. ReNerve confirms that initial product orders have been placed and fulfilled.

The agreement provides flexibility to adjust targets for external factors, and consequences for underperformance apply only in limited circumstances of sustained shortfall.

Termination

The agreement includes customary termination rights, including for material breach and at the end of the term with six (6) months' notice.

Summary

The Company notes that the agreement provides a commercial framework designed to support long-term market development, including:

- an initial exclusive term with potential extension to five years;
- performance expectations aligned to market development; and
- contractual flexibility to reflect the regulatory and commercial environment in the region.

- ENDS -



This announcement has been approved for release by the Company's Board of Directors.

For further information and enquiries, please contact:

Dr Julian Chick
CEO & Managing Director
ReNerve Ltd
+61 (03) 9482 3940
info@renerve.com.au

Matthew Wright
Investor & Media Relations
NWR Communications
+61 (0) 451 896 420
matt@nwrcommunications.com.au


About ReNerve Limited (ASX:RNV)

ReNerve Limited (ASX:RNV) is transforming nerve repair and improving lives through breakthrough medical technology. Founded by a neurosurgeon and medtech researchers, ReNerve is a rapidly growing medical device company that has revolutionised peripheral nerve surgery with its innovative, ready-to-use solutions for peripheral nerve injuries (PNI). Our scientifically backed products are delivering measurably better outcomes for patients worldwide.

Proven Clinical Success

ReNerve's first flagship product, the FDA-cleared **NervAlign® Nerve Cuff**, is already making a dramatic difference in surgical outcomes across the United States. A recently announced clinical study has demonstrated remarkable results, showing that patients treated with the NervAlign® Nerve Cuff experienced post-surgical pain scores dropping from 7.1 to just 0.4, compared to from 7.1 to 3.3 without the device being used – a statistically significant improvement that's changing lives.

Comparison of Patient Pre & Post Surgery Pain Score



Standard of Care vs NervAlign™ Nerve Cuff Protected Nerve Repairs

The comparison of pain scores between the two cohorts of patients

Comprehensive Product Portfolio

ReNerve is advancing a complete suite of nerve repair solutions and related surgical repairs:

On market

- **NervAlign® Nerve Cuff** – Our bioabsorbable protective wrap, naturally absorbed within six months of surgery.
- **Empliq™ Deep Dermal tissue product** -- A unique deep dermal product used in the repair of reconstructive and cosmetic surgical cases.
- **Empliq™ Amniotic tissue product ranges** -- Three amniotic tissue product ranges used to aid the healing of wounds.

In development

- **NervAlign® Nerve Conduit Range** – Next-generation nerve conduit leveraging advantages of eCOO technology in a material designed to facilitate nerve growth over short gaps between nerve ends.
- **NervAlign® Nerve Guide Matrix** – a customised and ready-to-use alternative to existing nerve grafts, for treatment of longer nerve gaps and more severe nerve injuries. It will eliminate the need for patients to undergo additional sural nerve harvesting.
- **NervAlign® Bionic Nerve** – Next-generation combination technology for the most challenging nerve repairs.

Market Leadership and Growth

With demonstrated market traction since the Company's 2022 product launch, ReNerve achieved 53% revenue growth in FY25, reaching \$271k in sales and YTD FY2026 sales revenues showing further significant increases across its portfolio. Our high-margin, scalable products are positioning us as the go-to solution for surgeons seeking superior patient outcomes in the rapidly expanding global nerve repair market, valued at US\$1.6 billion in 2024 and is projected to reach \$6.2 billion by 2031.¹

Vision and Values

We're not just developing medical devices – we're engineering hope. By creating the ideal healing environment for nerve repair and regeneration, ReNerve bridges critical gaps in healthcare while empowering the human body's natural healing process. Our cleaner, safer, and more effective solutions represent the future of peripheral nerve surgery.

¹ Global Nerve Repair Biomaterials Market Research Report (2020 – 2031)